Allogene Therapeutics (ALLO)
NASDAQ:ALLO
Want to see ALLO full AI Analyst Report?
Earnings Data
Report Date
Aug 05, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.18Last Year’s EPS
-0.23Same Quarter Last Year
Strong Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed meaningful early clinical progress — notably a strong MRD clearance signal and ctDNA reduction for cema-cel, favorable outpatient safety signals, encouraging early activity and tolerability for ALLO-329, operational scale-up and a strengthened balance sheet that extends runway into 2029. Major caveats include small interim sample size, the preliminary nature of surrogate biomarker results pending EFS validation, continued dose escalation and limited ALLO-329 maturity, and increased 2026 operating expense guidance. On balance, the call emphasized advancing, differentiated clinical data and execution momentum while acknowledging near-term clinical and financial uncertainties.Company Guidance
ALPHA3 Interim MRD Efficacy Signal
Interim futility analysis (24 patients) showed MRD clearance of 58.3% for cema-cel vs 16.7% for observation — an absolute difference of 41.6 percentage points, supporting biological activity in first-line consolidation for LBCL.
Strong ctDNA Pharmacodynamic Response
At day 45 median circulating tumor DNA (ctDNA) decreased by ~98% in the cema-cel arm versus an increase of >26% in the observation arm, indicating rapid tumor burden reduction.
Favorable Early Safety and Outpatient Feasibility
No CRS, ICANS or treatment-related hospitalizations reported in the interim ALPHA3 cohort; majority of patients managed entirely in the outpatient setting, supporting potential community administration.
ALLO-329 Early Activity and Tolerability
RESOLUTION Phase I basket trial has treated 9 patients across initial cohorts (3 at 20M with LD, 3 at 40M with LD, 3 at 20M without LD). Investigators report early signs of clinical activity and favorable tolerability despite substantially lower cell doses than many competitors.
Dose Escalation Progress and Next Cohort
Dose escalation is ongoing for ALLO-329 with the next cohort at 80 million cells enrolling; company expects to include higher-dose patients in the Q4 2026 update.
Dagger Technology Validation and Supporting Data
ALLO-329 leverages Dagger technology designed to reduce allogeneic rejection; approach has prior clinical validation in ALLO-316 and supportive preclinical data published in Nature Communications.
Operational and Global Trial Expansion
ALPHA3 is scaling rapidly: enrolling across >60 sites with regulatory approvals and activations begun in Australia and South Korea and plans to expand the Asia-Pacific footprint to over 80 sites; community centers contributed ~1/3 of screening and treatments in the interim cohort.
Strengthened Balance Sheet and Extended Runway
Cash, cash equivalents and investments of $266.9M as of March 31, 2026, plus ~ $200.4M gross proceeds from April public offering, extending cash runway into Q1 2029.
Planned Milestones and Timelines
Company expects ALPHA3 enrollment completion end of 2027, interim EFS analysis mid-2027, primary EFS mid-2028 and plans to pursue a BLA based on those analyses; comprehensive ALLO-329 update planned for Q4 2026.
ALLO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ALLO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $2.33 | $2.14 | -8.15% |
Mar 12, 2026 | $2.47 | $2.40 | -2.83% |
Nov 06, 2025 | $1.05 | $1.18 | +12.38% |
Aug 13, 2025 | $1.04 | $1.07 | +2.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Allogene Therapeutics (ALLO) report earnings?
Allogene Therapeutics (ALLO) is schdueled to report earning on Aug 05, 2026, Before Open (Confirmed).
What is Allogene Therapeutics (ALLO) earnings time?
Allogene Therapeutics (ALLO) earnings time is at Aug 05, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALLO EPS forecast?
ALLO EPS forecast for the fiscal quarter 2026 (Q2) is -0.18.